drugmakers

Sabit12 haber6 kaynakSon güncelleme: 4 gün önce

İlgili Etiketlerdonald trump generic drugs tariffs drug prices trade policy healthcare pharmaceuticals FDA

Son Haberler

Trump's Proposed Tariffs on Generic Drugs Spark Concerns Over U.S. Production Shift

President Trump proposed tariffs up to 200% on imported generic medicines after a two-year grace period, aiming to boost U.S. production. The generic drug industry, operating on thin margins, warns that shifting manufacturing domestically within the timeframe is challenging and could lead to market exits or price increases, impacting patient access to affordable medicines.

CNBC World

5 dk okuma

Trump Announces Phased Tariffs on Generic Drug Imports to Boost Onshore Production

Gelişiyor

Siyaset·5 gün önceAI özeti

Trump Announces Phased Tariffs on Generic Drug Imports to Boost Onshore Production

President Trump announced zero tariffs on imported generic drugs for two years starting August 1, aiming to incentivize onshore production. Tariffs will then escalate to 100% in 2028 and 200% in 2029 for non-compliant companies, while patented drug tariffs remain unchanged.

CNBC

1 dk okuma

India to Crack Down on Drugmakers Selling Unlisted, Irrational Formulations

Gelişiyor

Business·08.07.2026AI özeti

India to Crack Down on Drugmakers Selling Unlisted, Irrational Formulations

India's government plans to penalize drugmakers with unlisted products to stop sales of irrational fixed-dose combinations. Expert committees suggest license cancellation for unapproved formulations, as previous measures failed to ensure compliance.

Economic Times

2 dk okuma

Anthropic Launches Internal Drug Discovery Program for Neglected Diseases

Gelişiyor

Teknoloji·30.06.2026AI özeti

Anthropic Launches Internal Drug Discovery Program for Neglected Diseases

Anthropic is launching an internal drug discovery program focused on neglected diseases, aiming to develop AI tools for drugmakers. The company believes direct experience is crucial for building effective AI solutions for the healthcare industry.

Tick Season May Be the Worst in a Decade, But a New Lyme Disease Vaccine Is on the Horizon

As tick season intensifies due to climate change, a new Lyme disease vaccine from Pfizer and Valneva may offer protection, but its acceptance among high-risk groups like hunters is uncertain amid vaccine skepticism.

NPR News

Drugmakers Envision Future of Obesity Treatments Beyond GLP-1s

Gelişiyor

Sağlık·13.06.2026AI özeti

Drugmakers Envision Future of Obesity Treatments Beyond GLP-1s

Drugmakers are exploring new obesity treatments beyond GLP-1s, including less frequent shots and pills with fewer side effects. Eli Lilly's experimental drug retatrutide showed significant weight loss, while competitors like Novo Nordisk, Structure Therapeutics, AstraZeneca, Pfizer, and Amgen are developing new oral and injectable options. The market is expected to grow significantly, with pricing and insurance coverage being key factors.

GSK to Acquire Nuvalent for $10.6 Billion to Boost Oncology Pipeline

GSK acquires Nuvalent for $10.6B to bolster oncology pipeline with late-stage lung cancer treatments, aiming to offset future revenue drop from losing HIV medicine exclusivity.

CNBC

4 dk okuma

Supreme Court Allows Mail Orders of Abortion Drug Mifepristone Pending Appeal

Gelişiyor

Law·14.05.2026AI özeti

Supreme Court Allows Mail Orders of Abortion Drug Mifepristone Pending Appeal

The Supreme Court has temporarily allowed mail orders of the abortion drug mifepristone while an appeal by Louisiana against the FDA's distribution rules is pending, with Justices Thomas and Alito dissenting.

FDA Commissioner Dr. Marty Makary Resigns Amid Controversy

Dr. Marty Makary resigned as FDA commissioner amid controversy and internal dysfunction, to be replaced by Kyle Diamantas as acting commissioner

CNBC US Markets

Trump says Makary is out as FDA commissioner, following industry and White House backlash

HABER

12.05.2026

Trump says Makary is out as FDA commissioner, following industry and White House backlash

Makary's tenure was marked by internal dysfunction at the FDA, leadership turmoil and mounting backlash from drugmakers and physicians on regulatory decisions.

CNBC US Markets

Regeneron Cuts Drug Prices for Some Americans in Trump Deal, Offers Free Gene Therapy

Gelişiyor

Sağlık·23.04.2026AI özeti

Regeneron Cuts Drug Prices for Some Americans in Trump Deal, Offers Free Gene Therapy

Regeneron agreed to lower U.S. drug prices for some Americans under a deal with President Trump, part of his 'most favored nation' effort to align U.S. prices with lower international rates. The biotech company will also offer its newly FDA-approved hearing-loss gene therapy Otarmeni for free to eligible patients. The agreements exempt companies from tariffs for three years, including planned up to 100% levies on pharmaceuticals. The FDA approved Otarmeni under its National Priority Voucher program for an ultra-rare genetic condition causing deafness.

CNBC

1 dk okuma

Bayer Warns of Higher Drug Prices in Europe Amid US Pricing Pressure

Gelişiyor

Business·13.04.2026AI özeti

Bayer Warns of Higher Drug Prices in Europe Amid US Pricing Pressure

Bayer's pharmaceutical head Stefan Oelrich warns that European drug prices must rise to maintain profitability as US policies force companies to lower costs for American consumers, leading to a decline in new drug launches across Europe.

RT Business

2 dk okuma